Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
576people in the Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes trial, from 2006
533of them with hypertension, in this paper
The trial randomly assignedassigned by chance
liraglutide (1.2 or 1.8 mg)
placebo
Reported lower A1C values, no range given−1.00
randomisedThe trial randomly assignedassigned by chance
liraglutide 1.2 mg
placebo
Reported lower systolic blood pressure, no range given−5.60
randomisedthe abstract, start to end
Mean A1C values decreased significantly …
Systolic blood pressure decreased by 6.7, 5.6, and 1.1 mmHg with 1.2 and 1.8 …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
A1C valuesliraglutide (1.2 or 1.8 mg) vs placebo
−1.00
Systolic blood pressureliraglutide 1.2 mg vs placebo
−5.60
GLP-1 receptor agonistsGlycemic controlBlood pressure
1 / 4